In a first, HKEX receives IPO pitch from local biotech looking to make it big in crowded antibodies field
A Hong Kong-based antibody maker has filed for an IPO on the HKEX, marking the first truly homegrown company to take advantage of new rules …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
